111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by investment analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.
111 Stock Down 1.5%
Shares of YI stock traded down $0.11 during trading hours on Tuesday, reaching $6.77. 8,583 shares of the stock traded hands, compared to its average volume of 6,817. 111 has a 1-year low of $4.14 and a 1-year high of $11.90. The business has a fifty day moving average price of $7.64 and a 200 day moving average price of $7.65. The firm has a market capitalization of $58.45 million, a PE ratio of -10.57 and a beta of 0.43.
111 (NASDAQ:YI - Get Free Report) last released its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $486.35 million for the quarter.
Institutional Trading of 111
Several large investors have recently modified their holdings of YI. Deuterium Capital Management LLC bought a new stake in shares of 111 during the 1st quarter worth $81,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in 111 in the 1st quarter valued at $92,000. JPMorgan Chase & Co. boosted its holdings in 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after purchasing an additional 305,339 shares during the period. Finally, FIL Ltd bought a new stake in 111 in the 4th quarter valued at $450,000. 21.32% of the stock is owned by institutional investors.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Recommended Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access